Neurocrine's 40% Growth Meets a Falling Stock: What the Nov. 2 Report Has to Prove

Neurocrine Biosciences (NBIX) will report third-quarter 2026 results on Monday, November 2, then walk analysts through them on a 4:30 p.m. conference call. Calendar news, on its face. But the stock enters that call at $141, down about 18% over the past three months and roughly 24% below its 52-week high of $186, while the business just posted one of the faster growth quarters in the biotech group. That gap between the tape and the fundamentals is what the report has to resolve.

The last quarter set a high bar. Q2 revenue came in at $959 million, up about 39.5% year over year against consensus near $891 million, and management used the call to raise full-year Ingrezza guidance to $2.825 billion to $2.875 billion from $2.7 billion to $2.8 billion.

The portfolio underneath is three first-in-class medicines stacked on one towering base. Ingrezza (valbenazine), the franchise drug for tardive dyskinesia and Huntington's chorea, did roughly $2.5 billion in 2025, about eight times its next-largest product, Crenessity (crinecerfont) for classic congenital adrenal hyperplasia, at around $301 million. The third rung is newly added: VYKAT XR (diazoxide choline), the first and only FDA-approved treatment for hyperphagia in Prader-Willi syndrome, which Neurocrine bought in April when it agreed to acquire Soleno Therapeutics for about $2.9 billion in cash, $53 a share, roughly a 34% premium. VYKAT brought in about $190 million in 2025, its first partial year.

November 2 is the first full quarter in which the newly acquired asset sits inside the consolidated numbers, which is exactly why the report matters. The "three first-in-class medicines" story is only a story until it shows up in the revenue line.

That is also where the cheap-looking headline number deserves a second look. The trailing multiple is about 20x earnings, versus a peer average near 52x, which is why the bulls' most-followed fair-value estimate runs around $207, a mark the stock sits roughly 30% below. But the twelve months of earnings that multiple sits on were not flattered by the June quarter's bottom line, which printed $1.39 per share against the roughly $1.66 analysts had modeled. A quarter that misses on the bottom line is a reminder that trailing multiples can diverge from the earnings power that persists.

The other reason the market stays cool sits in the same revenue line: concentration. Ingrezza is the company; Crenessity and VYKAT together are still a rounding error against it. Analysts flag pricing pressure on Ingrezza and safety concerns that could slow VYKAT's adoption, the standard list of reasons a "cheap" grower keeps getting cheaper.

The underperformance shows up against the market rather than against the business. Over the past year NBIX is up about 5% while the S&P 500 has returned roughly 16%, and it's up only about 2% year to date against a 13.6% index gain. Ainvest data shows the stock trading below its 50-day average with a slackening tape rather than a panic.

The deeper lesson for reading the report is that the reaction will matter more than the headline. This is a stock whose good news has gone unrewarded: it beat in Q2, raised guidance, and then spent the summer falling. A beat that merely confirms expectations can still trade down, so the number to watch is not whether revenue tops the near-$1.04 billion consensus with EPS near $1.91, but whether it moves the durable earnings story.

Three things are worth listening for on the call. First, Ingrezza's absolute growth: does the quarter track the raised $2.825 billion to $2.875 billion guidance, or show the mature tardive-dyskinesia franchise slowing? Second, the two launches: does Crenessity keep ramping, and does VYKAT's first consolidated quarter look like a launch with traction rather than a blip? Third, the balance between growth and cost: does management lift the year's number again, or start flagging the integration and pipeline-spend drag from a $2.9 billion deal?

The bull case is that this is a roughly $2.5 billion franchise growing near 40% at a trailing 20x multiple with two more products coming, with Guggenheim's $207 and UBS's $214 targets sitting well above the price. The bear case is the tape: a stock that fell 18% in three months and never caught a bid even after a blowout quarter. History on situations like this splits rather than leans. The November numbers answer it: if the new launches show up and Ingrezza holds its pace, the cheap label has something behind it. If VYKAT's first consolidated quarter underwhelms and Ingrezza's growth keeps decelerating, the multiple is cheap for a reason.